Akebia Therapeutics (AKBA) vs Amarin (AMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amarin (AMRN) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 37.6% versus a loss of 70.4%. Over five years, AKBA leads with a -69.4% price change compared with -88.4% for AMRN. Amarin is the larger company by market cap ($250.9 million vs $234.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | AMRN |
|---|---|---|
| Share price | $0.8451 | $11.88 |
| Market cap | $234.18M | $250.94M |
| 1-day change | -3.24% | -1.16% |
| YTD return | -45.75% | -13.90% |
| 1-year return | -70.39% | -37.62% |
| 5-year return | -69.35% | -88.35% |
| Forward P/E | — | 12.12 |
| EPS (TTM) | $-0.12 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $20.90 |
| 52-week low | $0.814 | $11.83 |
| Distance from 52-week high | -73.59% | -43.16% |
| Analyst consensus | none | none |
| Avg. price target upside | +363.85% | +5.22% |
| Average volume | 6.13M | 66.16K |
| Shares outstanding | 277.11M | 21.12M |
| Employees | 194 | 80 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRN has outperformed AKBA by 32.8 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
AKBA vs AMRN FAQ
Which is bigger, Akebia Therapeutics or Amarin?
Amarin (AMRN) is larger, with a market capitalization of $250.94M compared with $234.18M for Akebia Therapeutics (AKBA).
Which stock has performed better over the past year, AKBA or AMRN?
AMRN returned -37.62% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Amarin in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.